Abdul Manap Aimi Syamima, Almadodi Reema, Sultana Shirin, Sebastian Maheishinii Grace, Kavani Kenil Sureshbhai, Lyenouq Vanessa Elle, Shankar Aravind
Department of Biomedical Science, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.
Faculty of Pharmacy and Biomedical Sciences, MAHSA University, Selangor, Malaysia.
Front Aging Neurosci. 2024 Aug 9;16:1429211. doi: 10.3389/fnagi.2024.1429211. eCollection 2024.
The most prevalent cause of dementia is Alzheimer's disease. Cognitive decline and accelerating memory loss characterize it. Alzheimer's disease advances sequentially, starting with preclinical stages, followed by mild cognitive and/or behavioral impairment, and ultimately leading to Alzheimer's disease dementia. In recent years, healthcare providers have been advised to make an earlier diagnosis of Alzheimer's, prior to individuals developing Alzheimer's disease dementia. Regrettably, the identification of early-stage Alzheimer's disease in clinical settings can be arduous due to the tendency of patients and healthcare providers to disregard symptoms as typical signs of aging. Therefore, accurate and prompt diagnosis of Alzheimer's disease is essential in order to facilitate the development of disease-modifying and secondary preventive therapies prior to the onset of symptoms. There has been a notable shift in the goal of the diagnosis process, transitioning from merely confirming the presence of symptomatic AD to recognizing the illness in its early, asymptomatic phases. Understanding the evolution of disease-modifying therapies and putting effective diagnostic and therapeutic management into practice requires an understanding of this concept. The outcomes of this study will enhance in-depth knowledge of the current status of Alzheimer's disease's diagnosis and treatment, justifying the necessity for the quest for potential novel biomarkers that can contribute to determining the stage of the disease, particularly in its earliest stages. Interestingly, latest clinical trial status on pharmacological agents, the nonpharmacological treatments such as behavior modification, exercise, and cognitive training as well as alternative approach on phytochemicals as neuroprotective agents have been covered in detailed.
痴呆症最常见的病因是阿尔茨海默病。其特征为认知能力下降和记忆力加速丧失。阿尔茨海默病呈渐进性发展,始于临床前阶段,接着是轻度认知和/或行为障碍,最终导致阿尔茨海默病痴呆。近年来,建议医疗服务提供者在个体发展为阿尔茨海默病痴呆之前尽早诊断阿尔茨海默病。遗憾的是,在临床环境中识别早期阿尔茨海默病可能很困难,因为患者和医疗服务提供者倾向于将症状视为衰老的典型迹象而不予理会。因此,准确及时地诊断阿尔茨海默病至关重要,以便在症状出现之前促进疾病修饰和二级预防疗法的发展。诊断过程的目标发生了显著转变,从仅仅确认有症状的阿尔茨海默病的存在转变为在其早期无症状阶段识别该疾病。理解疾病修饰疗法的演变并将有效的诊断和治疗管理付诸实践需要理解这一概念。这项研究的结果将加深对阿尔茨海默病诊断和治疗现状的深入了解,证明寻求潜在的新型生物标志物的必要性,这些生物标志物有助于确定疾病阶段,尤其是在其最早阶段。有趣的是,详细介绍了最新的药物临床试验状态、行为改变、运动和认知训练等非药物治疗方法,以及植物化学物质作为神经保护剂的替代方法。